A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica)

W. M. Carroll, T. Saida, H. J. Kim, J. Kira, A. G. Kermode, C. P. Tsai, K. Fujihara, S. Kusunoki, M. Tanaka, K. K. Kim, D. Bates

研究成果: ジャーナルへの寄稿総説査読

9 被引用数 (Scopus)

抄録

Definite diagnosis of inflammatory demyelinating disease (multiple sclerosis (MS) and neuromyelitis optica (NMO)) may require time, but early treatment offers the opportunity to maximize patient outcomes. The purpose of this report is to provide guidance to facilitate early treatment decisions for patients with inflammatory demyelinating disease, before definitive diagnosis. Neurology experts reviewed the existing literature and clinical evidence. A treatment decision pathway was developed, defining patients for whom first-line MS disease-modifying therapies (a) are unlikely to be effective, (b) may be effective but require careful monitoring and (c) are likely to provide benefit. This algorithm seeks to ensure that patients, particularly those in Asia, receive appropriate treatment early in inflammatory demyelinating disease.

本文言語英語
ページ(範囲)1371-1380
ページ数10
ジャーナルMultiple Sclerosis Journal
19
10
DOI
出版ステータス出版済み - 9月 2013

!!!All Science Journal Classification (ASJC) codes

  • 神経学
  • 臨床神経学

フィンガープリント

「A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル